Boston Incubator Hosts Scottish Life Science Company, Symbiosis

November 13, 2012

BOSTON, Massachusetts (November 13, 2012) —A Scottish life sciences company has announced it is moving into Scottish Development International’s (SDI) Boston incubator office to allow it to target new business in the US.

Symbiosis Pharmaceutical Services, a leading small-scale contract manufacturer of novel injectable pharmaceuticals for use in clinical trials, currently has clients throughout Europe and Asia. It is now strategically targeting the US market to leverage its competitive strengths and address the growing demand for its pharmaceutical development services in the US, particularly from small to medium-sized biotechnology company clients. 

From the design stage onwards, Symbiosis configured its service offering to specifically meet the demands of the US market, which represents the largest global concentration of clinical trial clients. By establishing a foothold in the US, Symbiosis intends to increase its exposure with potential US biotechnology company clients and encourage more US firms to consider conducting their clinical trials in Scotland, benefitting from existing compliance with European, and often US, pharmaceutical regulations.

“Symbiosis is a great example of a young ambitious Scottish company that continues to look for new market opportunities overseas in order to grow its business,” said Danny Cusick, President, Americas, Scottish Development International.

“Moving into the SDI incubator in Boston will help them establish a base near to known potential US customers, and act as a springboard to establishing a more permanent presence in the US. Through our SDI staff on the ground in Boston and across the US, we’re looking forward to working with Symbiosis to realize their ambitious growth plans both in the US and in Scotland.”

Colin MacKay, founder and Chief Executive of Symbiosis said, “Symbiosis is rightly proud of the industry-leading GMP sterile pharmaceutical manufacturing facility we recently built in Stirling, Scotland. Equally, the flexible operational capability we have built and the service excellence which our people are highly motivated to subsequently provide to our clients, directly bolster our competitive strengths. Given the Symbiosis management team’s familiarity with the US biopharmaceutical industry, both the facility and the operations within it were designed and built with the demands of the US market in mind. In the spirit of a truly symbiotic relationship, we have a resolute belief that our service delivery will directly facilitate the successful achievement of our clients’ drug development milestones.

“Symbiosis is delighted to be moving into SDI’s Boston incubator as this will provide us with a powerful means of directly accessing the potential market in the US. We have an outstanding track record of helping our clients meet their clinical trial deadlines. Our intention is to be the fastest and the best small-scale sterile pharmaceutical manufacturing company in the world. This step represents another example of how practical, proactive support from Scottish Enterprise and Scottish Development International has directly facilited the development and growth of Symbiosis both in Scotland and its entry into attractive international markets like the US.”

About Symbiosis

Symbiosis was founded in 2011 in Stirling, Scotland and employs 17 people. It is a world-class pharmaceutical Contract Manufacturing Organization (CMO) with a highly experienced management team. Symbiosis specializes in the small-scale manufacture of sterile liquid and lyophilised pharmaceutical products for use in phase I and phase II clinical trials. It has specialist capabilities to handle either biologic, cytotoxic or highly potent pharmaceuticals and has a global client base. The company's competitive strength stems from providing service excellence. This is founded on an excellent electronic quality system and a strong technical knowledge which it leverages to reduce the time it takes its clients to develop their pharmaceuticals.

To find out more please visit www.symbiosis-pharma.com

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.